- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02137161
Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery (REPEX)
The Reggio Emilia Study on Bromfenac for Patients With PseudoEXfoliation Syndrome Undergoing Cataract Surgery: the REPEX Study
OBJECTIVE To evaluate the efficacy of bromfenac ophthalmic solution 0.09% for reducing postoperative inflammation in eyes with pseudoexfoliation syndrome (PEX) undergoing cataract surgery and receiving standard postoperative eye drops (dexamethasone 0.1% plus tobramycin 0.3% ophthalmic solution).
DESIGN Two arms, parallel group, randomized, single center, prospective, phase IV clinical trial.
PARTICIPANTS Sixty-two subjects with PEX and cataract will be sequentially assigned, according to a computer-generated randomization list (1:1), to bromfenac (n = 31) or not (n = 31).
INTERVENTION Cataract surgery by means of phacoemulsification and implantation of posterior-chamber intraocular lens will be performed by two experienced ophthalmic surgeons.
Standard Arm: only a standard antibiotic and steroid ophthalmic suspension will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week (dexamethasone 0.1% and tobramycin 0.3% eye drops association).
Experimental Arm: eyes will receive bromfenac BID for two weeks starting the day after surgery. Standard post-operative topical antibiotic and steroid will be also given concurrently, dosed QID for the first week and BID for the second week (dexamethasone 0.1% and tobramycin 0.3% eye drops association).
Measurements will be carried out at baseline and after one day, 3 days, 1 week and 4 weeks from cataract extraction.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
RE
-
Reggio Emilia, RE, Italy, 42123
- Arcispedale Santa Maria Nuova IRCSS - Ophthalmology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- cataract
- pseudoexfoliation syndrome
Exclusion Criteria:
- history of ocular inflammation or trauma
- previous intraocular surgery
- corneal haze
- retinal vascular disease
- diabetic retinopathy
- variation of the foveal profile at OCT (macular edema, epiretinal membrane)
- moderate to severe age related macular degeneration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Dexamethasone+Tobramycin eye drop
An antibiotic and steroid eye drop association will be given starting the day after the surgery for two weeks, dosed QID for the first week and BID for the second week, to 31 patients.
|
dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
|
Experimental: Bromfenac
Bromfenac eye drops (BID for two weeks starting the day after surgery) plus an antibiotic and steroid eye drop association (QID for the first week and BID for the second week) will be given concurrently to 31 patients.
|
dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
bromfenac ophthalmic solution 0.09%
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in anterior chamber inflammation measured by Laser Flare Photometry (photon counts per millisecond)
Time Frame: Baseline, Day 3
|
Reduction of 30% of anterior chamber inflammation evaluated by Laser Flare Photometry (LFP) in the bromfenac arm when compared to the non-bromfenac arm at postoperative day 3.
|
Baseline, Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients with central macular thickness greater than 300 microns
Time Frame: Baseline, Week 4
|
Macular thickness will be evaluated by Spectral Domain Optical Coherence Tomography (SD-OCT).
|
Baseline, Week 4
|
Proportion of subjects with best corrected visual acuity equal to 20/20
Time Frame: Baseline, Week 1
|
Baseline, Week 1
|
|
Proportion of patients who had no ocular pain
Time Frame: Baseline, Day 3
|
Baseline, Day 3
|
Collaborators and Investigators
Investigators
- Principal Investigator: Marco Coassin, MD PhD, Arcispedale S. Maria Nuova IRCCS
- Study Chair: Luigi Fontana, MD PhD, Arcispedale S. Maria Nuova IRCCS
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Eye Diseases
- Disease
- Uveal Diseases
- Lens Diseases
- Iris Diseases
- Syndrome
- Cataract
- Exfoliation Syndrome
- Physiological Effects of Drugs
- Anti-Infective Agents
- Autonomic Agents
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Anti-Bacterial Agents
- Pharmaceutical Solutions
- Dexamethasone
- Ophthalmic Solutions
- Tobramycin
- Bromfenac
- Tobramycin, Dexamethasone Drug Combination
Other Study ID Numbers
- 2013-002066-39
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cataract
-
Fundación Pública Andaluza para la Investigación...CompletedCataract | Cataract Mature | Cataract, Nuclear
-
Johannes Kepler University of LinzCompletedCataract Complicated | Cataract Complications OperationsAustria
-
Gemini Eye ClinicRecruitingBilateral Cataract | Unilateral CataractCzechia
-
Universitaire Ziekenhuizen KU LeuvenLaboratoires TheaRecruiting
-
Omer Othman AbdullahCompletedCongenital Cataract | Pediatric CataractIraq
-
Yonsei UniversityCompletedCataract PatientsKorea, Republic of
-
Johannes Kepler University of LinzRecruitingAphakia | Secondary Cataract Surgery | Complicated Cataract SurgeryAustria
-
National University Hospital, SingaporeSingapore General HospitalCompletedCataract Surgery | Stress Levels | Music Improving Outcomes in Cataract SurgerySingapore
-
Advanced Center for Eyecare GlobalNot yet recruiting
-
Vienna Institute for Research in Ocular SurgeryRecruiting
Clinical Trials on Dexamethasone+Tobramycin eye drop
-
Sun Yat-sen UniversityUnknownAge-related CataractChina
-
Wolfson Medical CenterUnknown
-
Massachusetts Eye and Ear InfirmaryBausch & Lomb IncorporatedCompletedEfficacy of Zylet vs. Lotemax for the Treatment of Ocular Surface Inflammation/MGD/Blepharitis (ZvL)Meibomian Gland Dysfunction | Posterior BlepharitisUnited States
-
The Norwegian Dry Eye ClinicLaboratoires TheaRecruiting
-
University of RochesterBausch & Lomb IncorporatedCompletedAqueous Deficient Dry Eye | Meibomium Gland DysfunctionUnited States
-
Alcon ResearchCompleted
-
AllerganCompletedContact Lens LubricationUnited States
-
Mahidol UniversityCompletedEfficacy of 0.05 % Cyclosporine Ophthalmic Emulsion Compare With Tear in Meibomian Gland DysfunctionMeibomian Gland DysfunctionThailand
-
Alcon ResearchCompleted